Nursing high dose intravenous immunoglobulin therapy of Kawasaki disease

Ni LF, Liu XL, Wang Li, Wu M, Liao JX, Li CR

Shenzhen Childrens Hospital, Shenzhen 518026, China

 

Objective: To explore the nursing of high dose intravenous immunoglobulin (hdIVIg) therapy of Kawasaki disease, its efficacy and safety.

Methods: 71 patients with Kawasaki disease were retrospectively reviewed about the dosage, administration, intravenous drip duration, efficacy, and nursing.

Results: From December 1999 to February 2001 there were 60 of 71 patients with Kawasaki disease accepted hdIVIg as major treatment. 10() treated with 1g/kg body weight, 49(81.67%) with 2g/kg intravenous immunoglobulin. The concentration of immunoglobulin was 5%. The drip speed started slowly, if there was no any adverse reaction after 15 minutes, the speed might increased to no more than 2ml/minutes. 15(25%) completed the regimen within one day, and 35(58.33%) completed the regimen within two days. Fever disappeared within 24 hours in 30 of 60 patients, and another 20 within the second 24 hours. By one month after the disease onset, only one patient had coronary artery aneurysm. Only one patient complained having headache, looked pale, but the life signs was normal, and ultimately completed the treatment.

Conclusion: High dose of intravenous immunoglobulin therapy of Kawasaki disease is efficacious and safe. We cumulated many experiences about the nursing of hdIVIg therapy.

 
0473